A Phase 1/2 Study of a First-in-Class Non-Cellular Antibody-Drug Conjugate, Micvotabart Pelidotin (MICVO), in Combination with Pembrolizumab in Select Advanced Solid Tumors – Abstract Number: 548 By Dan A Phase 1/2 Study of a First-in-Class Non-Cellular Antibody-Drug Conjugate, Micvotabart Pelidotin (MICVO), in Combination with Pembrolizumab in Select Advanced Solid Tumors – Abstract Number: 548 Read More »
Micvotabart pelidotin induces immunogenic cell death markers and activates tumor immune cells in pre-clinical studies – Abstract Number: A112 By Dan Micvotabart pelidotin induces immunogenic cell death markers and activates tumor immune cells in pre-clinical studies – Abstract Number: A112 Read More »
Micvotabart pelidotin, an ADC targeting non-cellular EDB+FN, induces an immune response in tumors from participants in a phase 1 dose escalation study – Abstract Number: A114 By Dan Micvotabart pelidotin, an ADC targeting non-cellular EDB+FN, induces an immune response in tumors from participants in a phase 1 dose escalation study – Abstract Number: A114 Read More »
Characterization of micvotabart pelidotin target binding properties and extracellular payload release – Abstract Number: A116 By Dan Characterization of micvotabart pelidotin target binding properties and extracellular payload release – Abstract Number: A116 Read More »
Development of multiplex immunofluorescence workflows for characterizing tumor-immune and stromal compartments for pharmacodynamic assessments of solid tumors – Abstract Number: A117 By Dan Development of multiplex immunofluorescence workflows for characterizing tumor-immune and stromal compartments for pharmacodynamic assessments of solid tumors – Abstract Number: A117 Read More »
Mouse analog of micvotabart pelidotin sensitizes a refractory syngeneic breast cancer model to anti-PD1 therapy – Abstract Number: A115 By Dan Mouse analog of micvotabart pelidotin sensitizes a refractory syngeneic breast cancer model to anti-PD1 therapy – Abstract Number: A115 Read More »
Micvotabart pelidotin, a non-cellular targeting ADC, remodels the tumor microenvironment in tumors from participants in a phase 1 dose escalation study – Abstract Number: A113 By Dan Micvotabart pelidotin, a non-cellular targeting ADC, remodels the tumor microenvironment in tumors from participants in a phase 1 dose escalation study – Abstract Number: A113 Read More »
A Phase 1/2 Study of a First-in-Class Non-Cellular Antibody-Drug Conjugate, Micvotabart Pelidotin (MICVO), in Combination with Pembrolizumab in Select Advanced Solid Tumors – Abstract Number: 1025 By Dan A Phase 1/2 Study of a First-in-Class Non-Cellular Antibody-Drug Conjugate, Micvotabart Pelidotin (MICVO), in Combination with Pembrolizumab in Select Advanced Solid Tumors – Abstract Number: 1025 Read More »
Phase 1 Expansion Study of the First-in-Concept Extracellular Antibody-Drug Conjugate (ADC), Micvotabart Pelidotin (MICVO), in Patients with Select Advanced Solid Tumors – Abstract Number: 1031 By Dan Phase 1 Expansion Study of the First-in-Concept Extracellular Antibody-Drug Conjugate (ADC), Micvotabart Pelidotin (MICVO), in Patients with Select Advanced Solid Tumors – Abstract Number: 1031 Read More »
Histological biomarker analysis of nonclinical and baseline tumor samples from the phase 1 dose escalation study using micvotabart pelidotin (MICVO) in advanced solid tumors – Abstract Number: 1014 By Dan Histological biomarker analysis of nonclinical and baseline tumor samples from the phase 1 dose escalation study using micvotabart pelidotin (MICVO) in advanced solid tumors – Abstract Number: 1014 Read More »
